- Home
- URGN vs BIGC Comparison
URGN vs BIGC Comparison
Compare URGN & BIGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- BIGC
- Stock Information
- Founded
- URGN 2004
- BIGC 2009
- Country
- URGN United States
- BIGC United States
- Employees
- URGN N/A
- BIGC N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- BIGC Computer Software: Prepackaged Software
- Sector
- URGN Health Care
- BIGC Technology
- Exchange
- URGN Nasdaq
- BIGC Nasdaq
- Market Cap
- URGN 463.2M
- BIGC 426.0M
- IPO Year
- URGN 2017
- BIGC 2020
- Fundamental
- Price
- URGN $10.38
- BIGC $5.16
- Analyst Decision
- URGN Strong Buy
- BIGC Hold
- Analyst Count
- URGN 7
- BIGC 7
- Target Price
- URGN $36.75
- BIGC $7.64
- AVG Volume (30 Days)
- URGN 635.6K
- BIGC 709.1K
- Earning Date
- URGN 05-12-2025
- BIGC 05-08-2025
- Dividend Yield
- URGN N/A
- BIGC N/A
- EPS Growth
- URGN N/A
- BIGC N/A
- EPS
- URGN N/A
- BIGC N/A
- Revenue
- URGN $90,398,000.00
- BIGC $334,937,000.00
- Revenue This Year
- URGN $36.82
- BIGC $5.65
- Revenue Next Year
- URGN $119.10
- BIGC $5.48
- P/E Ratio
- URGN N/A
- BIGC N/A
- Revenue Growth
- URGN 9.29
- BIGC 5.33
- 52 Week Low
- URGN $8.94
- BIGC $4.85
- 52 Week High
- URGN $20.70
- BIGC $8.60
- Technical
- Relative Strength Index (RSI)
- URGN 48.46
- BIGC 43.12
- Support Level
- URGN $9.63
- BIGC $5.09
- Resistance Level
- URGN $11.75
- BIGC $5.47
- Average True Range (ATR)
- URGN 0.82
- BIGC 0.19
- MACD
- URGN -0.02
- BIGC 0.04
- Stochastic Oscillator
- URGN 32.90
- BIGC 50.41
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About BIGC BigCommerce Holdings Inc. Series 1
BigCommerce Holdings Inc is engaged in offering Software-as-a-service (SaaS) e-commerce platform. The company's SaaS platform engages in the creation of online stores by delivering a combination of ease-of-use, enterprise functionality, and flexibility. It powers both the customers' branded ecommerce stores and their cross-channel connections to popular online marketplaces, social networks, and offline point-of-sale systems. The group operates in a single segment covering geographical areas of Americas-U.S.; Americas-other; EMEA; and APAC, of which majority of revenue is generated from Americas-U.S.